The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer

Abstract

BackgroundWhether PET scan maximum standard uptake value (SUVmax) could differentiate luminal A from luminal B and help predict the survival of metastatic breast cancer (MBC) patients with luminal subtype is still unknown and need to be investigated.Methods305 MBC patients with luminal subtypes were screened with PET/CT. Eligible patients were prospectively followed up.ResultsIn total, 134 patients were eligible for this study. SUVmax was significantly related to the number of metastatic sites and presence of visceral metastasis on univariate analysis. SUVmax could not effectively differentiate patients with luminal A from luminal B subtype. Although luminal subtype at diagnosis could predict the relapse-free interval, it could not predict progression-free survival (PFS) or overall survival (OS) after developing relapse. In contrast, SUVmax was predictive of both PFS and OS and this effect was maintained in multivariate COX regression model.ConclusionsSUVmax of MBC did not correlate with molecular subtypes of primary tumor. While molecular subtype may be a valuable prognostic factor at primary diagnosis of breast cancer, the SUVmax, rather than molecular subtype, does have a potential to predict independently in multivariate analysis for the PFS and OS in patients with metastatic disease of luminal subtype.

Pretreatment 18F-FDG Uptake Heterogeneity Predicts Treatment Outcome of First-Line Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer

“…Although SUVmax has been widely used as a prognostic biomarker in various primary tumors [21,[33][34][35][36], its role in metastatic breast cancer (MBC) has not been fully understood. Zhang et al [37] and Cokmert et al [38] have proven the prognostic value of SUVmax in patients with ER-positive and unselected MBC. The only study conducted in mTNBC cohort, however, showed that SUVmax was not significantly correlated with OS [39].…”

Total Lesion Glycolysis Using 18F-FDG PET/CT as a Prognostic Factor for Locally Advanced Esophageal Cancer

“…SUV is frequently used to evaluate tumor response and survival outcomes in various cancers such as breast, head and neck, and lung cancers ( 9 10 11 ). The SUV of primary esophageal cancer tumors has been reported to be significantly associated with OS, progression-free survival, local control, and response to concurrent CRT ( 12 13 ).…”

Whole-Body Metabolic Tumor Volume, as Determined by 18F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis

“…Morris et al [21] showed that the SUV max in metastatic bone lesions was strongly correlated with OS, whereas Zhang et al [22] reported that the pSUV max noted at baseline was significantly associated with prognosis and outcome in terms of progression-free survival and OS. Thus, SUV max emerged as a potential surrogate marker of survival in patients with metastatic disease.…”